Abstract
Background
Cigarette smoking is an important risk factor for abdominal obesity. However, the degree to which the CYP2A6 genotype moderates the relationship between smoking and abdominal obesity has not been established.
Purpose
This study aims to investigate whether or not the relationship between smoking quantity and abdominal obesity is influenced by CYP2A6 genotypes.
Methods
Nine hundred fifty-four male current smokers were selected. A venous specimen was collected to test serum cotinine and CYP2A6 genotype, and all smokers were divided into heavy (>15 cigarettes/day) and light smokers (≤15 cigarettes/day).
Results
Heavy smoking increased the risk of abdominal obesity (odds ratio (OR) = 1.57; 95% CI, 1.13–2.19) compared with light smoking. Furthermore, heavy smoking had a positive interactive effect with CYP2A6 poor metabolizer genotype on abdominal obesity (OR = 3.90; 95% CI, 1.25–12.18). Moreover, CYP2A6 poor metabolizer genotypes were associated with slower nicotine metabolism.
Conclusions
Heavy smoking may increase the risk of abdominal obesity—particularly in smokers with CYP2A6 poor metabolizer genotypes.
Similar content being viewed by others
References
Prentice AM, Jebb SA: Beyond body mass index. Obes Rev 2001, 2: 141–147.
World Health Organization: Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894: i–xii, 1–253.
Corrada MM, Kawas CH, Mozaffar F, Paganini-Hill A: Association of body mass index and weight change with all-cause mortality in the elderly. Am J Epidemiol 2006, 163: 938–949.
Albanes D, Jones DY, Micozzi MS, Mattson ME: Associations between smoking and body weight in the US population: Analysis of NHANES II. Am J Public Health 1987, 77: 439–444.
Bamia C, Trichopoulou A, Lenas D, Trichopoulos D: Tobacco smoking in relation to body fat mass and distribution in a general population sample. Int J Obes Relat Metab Disord 2004, 28: 1091–1096.
Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N et al.: Cigarette smoking and fat distribution in 21,828 British men and women: A population-based study. Obes Res 2005, 13: 1466–1475.
Kannel WB, D'Agostino RB, Cobb JL: Effect of weight on cardiovascular disease. Am J Clin Nutr 1996, 63: 419S-422S.
Resnick HE, Valsania P, Halter JB, Lin X: Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000, 54: 596–602.
U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, 1992. Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. EPA/600/6-90/006F, pp 44–96.
Pasupathi P, Bakthavathsalam G, Rao YY, Farook J: Cigarette smoking—Effect of metabolic health risk: A review. Diabetes & Metabolic Syndrome 2009, 3: 120–127.
Tanko LB, Christiansen C: An update on the antiestrogenic effect of smoking: A literature review with implications for researchers and practitioners. Menopause 2004, 11: 104–109.
Sulander T, Rahkonen O, Nissinen A, Uutela A: Association of smoking status with obesity and diabetes among elderly people. Arch Gerontol Geriatr 2007, 45: 159–167.
Gilbert DG, Meliska CJ, Williams CL, Jensen RA: Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology 1992, 106: 275–281.
Hukkanen J, Jacob P, Benowitz NL: Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57: 79–115.
Nakajima M, Yokoi T: Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005, 20: 227–235.
Mwenifumbo JC, Tyndale RF: Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007, 8: 1385–1402.
Wang H, Qiu Q, Tan LL, Liu T, Deng XQ, Chen YM et al: Prevalence and determinants of diabetes and impaired fasting glucose among urban community-dwelling adults in Guangzhou, China. Diabetes Metab 2009, 35: 378–384.
Centers for Disease Control: National Health Interview Survey: Early release of selected estimates based on data from January to September 2007. Available at www.cdc.gov. Accessed 1 April 2011.
Wen W, Xiang YB, Zheng W, Xu WH, Yang G, Li H et al: The association of alcohol, tea, and other modifiable lifestyle factors with myocardial infarction and stroke in Chinese men. CVD Prev Control 2008, 3: 133–140.
Park MS, Chung SY, Chang Y, Kim K: Physical activity and physical fitness as predictors of all-cause mortality in Korean men. J Korean Med Sci 2009, 24: 13–9.
WHO/IASO/IOTF: The Asia-Pacific perspective: Redefining obesity and its treatment. Melbourne: Health Communications Australia. 2000.
Coorperative Meta-analysis Group of China Obesity Task Force: Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chin J Epidemiol 2002, 23: 5–10.
Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M et al: Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010, 87: 553–557.
Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF: Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004, 14: 615–626.
Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A et al: Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 1999, 460: 321–327.
Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF: Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 2005, 15: 189–192.
Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T: CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J 2006, 6: 401–412.
Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF: A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008, 18: 67–75.
Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P et al: Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 2011, 105: 985–994
Rothman KJ, Greenland S, Lash TL: Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia. 2008, 58.
Rose KM, Newman B, Mayer-Davis EJ, Selby JV: Genetic and behavioral determinants of waist-hip ratio and waist circumference in women twins. Obes Res 1998, 6: 383–392.
Troisi RJ, Heinold JW, Vokonas PS, Weiss ST: Cigarette smoking, dietary intake, and physical activity: Effects on body fat distribution--the Normative Aging Study. Am J Clin Nutr 1991, 53: 1104–1111.
Simon JA, Seeley DG, Lipschutz RC, Vittinghoff E, Browner WS: The relation of smoking to waist-to-hip ratio and diabetes mellitus among elderly women. Prev Med 1997, 26: 639–644.
Akbartabartoori M, Lean ME, Hankey CR: Relationships between cigarette smoking, body size and body shape. Int J Obes 2005, 29: 236–243.
Shimokata H, Muller DC, Andres R: Studies in the distribution of body fat. III. Effects of cigarette smoking. JAMA 1989, 261: 1169–1173.
Mizuno O, Okamoto K, Sawada M, Mimura M, Watanabe T, Morishita T: Obesity and smoking: Relationship with waist circumference and obesity-related disorders in men undergoing a health screening. J Atheroscler Thromb 2005, 12: 199–204.
Molenaar EA, Massaro JM, Jacques PF, Pou KM, Ellison RC, Hoffmann K et al: Association of lifestyle factors with abdominal subcutaneous and visceral adiposity: The Framingham Heart Study. Diabetes Care 2009, 32: 505–510.
Hideaki K, Yutaka M, Takuo YTN: Smoking as a Risk Factor for Visceral Fat Accumulation in Japanese Men. Tohoku J Exp Med 2006, 208: 123–132.
Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J: Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2007, 298: 2654–2664.
Koh-Banerjee P, Chu NF, Spiegelman D, Rosner B, Colditz G, Willett W et al: Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am J Clin Nutr 2003, 78: 719–727.
Rossini A, de Almeida Simao T, Albano RM, Pinto LF: CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics 2008, 9: 1737–1752.
Pianezza ML, Sellers EM, Tyndale RF: Nicotine metabolism defect reduces smoking. Nature 1998, 393: 750.
Tyndale RF, Sellers EM: Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002, 24: 163–171.
Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H: Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochem Biophys Res Commun 2005, 338: 306–310.
Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M et al: Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004, 25: 2451–2458.
Derby KS, Cuthrell K, Caberto C, Carmella SG, Franke AA, Hecht SS et al: Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 2008, 17: 3526–3535.
Tiwawech D, Srivatanakul P, Karalak A, Ishida T: Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett 2006, 241: 135–141.
Kadlubar S, Anderson JP, Sweeney C, Gross MD, Lang NP, Kadlubar FF et al: Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP 2009, 10: 263–270.
Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP: Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 2009, 32: 416–423.
Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D: Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutat Res 2009, 669: 36–41.
Nakajima M, Kuroiwa Y, Yokoi T: Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab Rev 2002, 34: 865–877.
Acknowledgments
This study was funded by the Guangzhou Health Bureau (2005-Zda-001). National Institute on Drug Abuse/National Institutes of Health grants K08-014276 and R21-027331. We also acknowledge the financial support from the Centre for Addiction and Mental Health (RFT QZ) and Canadian Institutes for Health Research MOP86471. This study was completed with the assistance of the following units: Disease Prevention and Control Center of Haizhu District and Baiyun District, the Health Inspection Institute of Huangpu District, the Sixth Affiliated Hospital of Sun Yat-sen University, and the Health Care Center of Huayin Community, Jinyang Community, Longteng Community, and the Department of Health Education of Liwan Hospital.
Conflicts of interest statement
Dr. Tyndale owns shares and participates in Nicogen Research Inc., a company focused on novel smoking cessation treatment approaches. No Nicogen funds were used in this work, and no other Nicogen participants reviewed the manuscript. Dr. Tyndale has also consulted for Novartis. All other authors have no conflicts of interests to declare.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Liu, T., David, S.P., Tyndale, R.F. et al. Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers. ann. behav. med. 43, 253–261 (2012). https://doi.org/10.1007/s12160-011-9318-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12160-011-9318-5